Date: 2014-10-22
Type of information: Private placement
Company: Tetraphase Pharmaceuticals (USA - MA)
Investors:
Amount: $86.3 million
Funding type: private placement
Planned used:
Others: * On October 22, 2014, Tetraphase Pharmaceuticals announced the closing of its underwritten public offering of 4,542,500 shares of common stock at an offering price of $19.00 per share. The shares of common stock issued and sold in the offering at the closing include 592,500 shares issued upon the exercise in full by the underwriters of their option at the offering price. The gross proceeds to Tetraphase from this offering were $86.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Tetraphase. * On October16, 2014, Tetraphase Pharmaceuticals announced the pricing of an underwritten public offering of 3,950,000 shares of common stock for a public offering price of $19.00 per share. The gross proceeds to Tetraphase from this offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions and offering expenses payable by Tetraphase. * On October15, 2014, Tetraphase Pharmaceuticals announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Tetraphase. BMO Capital Markets, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering and JMP Securities and Needham & Company are acting as co-managers for the offering. Tetraphase intends to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area: Infectious diseases
